Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study (IMAGE)

Elsevier

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study

Caption

Findings published in the Journal of Hepatology establish a new survival benchmark for people living with advanced biliary tract cancer, reinforcing the efficacy of the combination therapy of durvalumab plus gemcitabine and cisplatin (GemCis) as the standard first-line treatment.

Credit

Journal of Hepatology / Oh et al.

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.